Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early-onset Lafora body disease.

Julie Turnbull1, Jean-Marie Girard, Hannes Lohi

  • 1Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario M5G 1L7, Canada.

Brain : a Journal of Neurology
|September 11, 2012
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropsychological functioning and progression in Lafora disease.

Epilepsia·2026
Same author

FRRS1L gene replacement ameliorates disease phenotypes in the mouse model of developmental and epileptic encephalopathy 37.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Steriwave® a Non-Antibiotic Nasal Photodisinfection Strategy Reduces Infection Burden In Endoscopic Skull Base Surgery.

The Journal of laryngology and otology·2026
Same author

Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Career Plans Among Graduating US Emergency Medicine Residents.

JAMA network open·2026
Same author

Neurofilament Light Chain as a Biomarker of Disease Progression in Lafora Disease.

Neurology. Genetics·2025

A new form of Lafora body disease, presenting in early childhood with distinct neurological symptoms, has been identified. This early-onset Lafora body disease involves mutations in the PRDM8 gene, affecting protein interactions crucial for glycogen metabolism.

Area of Science:

  • Neurogenetics
  • Molecular Neurology
  • Epilepsy Research

Background:

  • Progressive myoclonus epilepsies (PMEs) include neuronal ceroid lipofuscinoses and Lafora disease.
  • Lafora disease is characterized by Lafora bodies, pathognomonic polyglucosan aggregates, with onset in teenage years and a fatal 10-year course.
  • Lafora disease arises from mutations in EPM2A or EPM2B, affecting glycogen metabolism regulation.

Purpose of the Study:

  • To report a novel PME associated with Lafora bodies, termed early-onset Lafora body disease.
  • To map the genetic locus, identify the causative gene and mutation, and elucidate the molecular mechanism.
  • To characterize the interaction of the novel gene product with known Lafora disease proteins.

Main Methods:

  • Genetic locus mapping to chromosome 4q21.21.

Related Experiment Videos

  • Gene identification and mutation analysis (c.781T>C, Phe261Leu in PRDM8).
  • Protein interaction studies (PRDM8 with laforin and malin) and subcellular localization analysis.

    • Main Results:

    • Early-onset Lafora body disease presents at age 5 with dysarthria, myoclonus, and ataxia, distinct from typical Lafora disease.
    • Pathology confirmed Lafora bodies but not ceroid lipofuscinosis.
    • The PRDM8 Phe261Leu mutation causes nuclear sequestration of laforin and malin, suggesting a gain-of-function mechanism and cytoplasmic deficiency.

    Conclusions:

    • A new PME, early-onset Lafora body disease, has been identified, caused by PRDM8 mutations.
    • PRDM8 protein interacts with laforin and malin, regulating their cytoplasmic levels.
    • This discovery expands the spectrum of Lafora body diseases and highlights PRDM8's role in glycogen metabolism regulation.